Technical Note

The Modulatory Effects of A2AR on NMDAR Functionality Using Primary Neurons and Microglia Cultures for Potential Neuroprotection in Alzheimer's Disease

Modulatory effects of A2AR on NMDAR in Alzheimer's


In the field of neurodegenerative disease therapies, there is continued interest in exploring not only the basic mechanism of how the drug is eliciting a protective effect against symptoms, but also synergistic cellular pathways that may have an additive effect in increasing the effectiveness of existing therapies or be applicable to other neurodegenerative diseases that may share similar symptoms. For those impacted by Alzheimer’s Disease (AD), two main types of drugs exist on the market that either modulate the N-methyl D-aspartate ionotropic glutamate receptor (NMDAR) or are Acetylcholinesterase inhibitors (AchEIs). These drugs that act on NMDARs are purposefully designed to be weak negative allosteric modulators to elicit sufficient response without becoming toxic. At this time, all available therapies currently only delay progression of symptoms and are not disease modifying.